Healthcare Services

Global Chlamydia Market Set for Strong Expansion Reaching $4.85 Billion by 2030 at 8.5% CAGR

March 31, 2026April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Chlamydia Market By 2030 Starting From Its 2026 Size?

The chlamydia market size has demonstrated robust growth over recent years. It is anticipated to expand from $3.23 billion in 2025 to $3.51 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.8%. This historical growth can be linked to a number of factors including the increasing prevalence of sexually transmitted infections, the wider implementation of public health screening programs, enhanced access to diagnostic laboratories, a rise in awareness regarding reproductive health, and the existence of various antibiotic treatment options.

The chlamydia market is projected to experience substantial expansion in the coming years. By 2030, this market is anticipated to reach a valuation of $4.86 billion, exhibiting a compound annual growth rate (CAGR) of 8.5%. This projected growth can be attributed to several factors including an increased demand for point-of-care diagnostics, an intensified focus on preventive sexual healthcare, the expansion of digital health screening platforms, rising investments in diagnostic innovation, and the proliferation of government-led STI control initiatives. Key trends expected during the forecast period encompass a greater adoption of rapid chlamydia testing methods, an increased utilization of NAAT-based diagnostic techniques, a heightened emphasis on early STI screening programs, the development of home-based testing solutions, and improved awareness of asymptomatic infections.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21138&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Chlamydia Market?

The rising prevalence of sexually transmitted diseases is anticipated to propel the growth of the chlamydia market moving forward. Sexually transmitted diseases (STDs) are infections that spread through sexual contact, including chlamydia, gonorrhea, and HIV. The increase in STDs is linked to factors such as reduced condom use, a lack of public awareness, limited access to healthcare services, and the widespread use of dating applications that facilitate multiple sexual partners. Chlamydia treatment helps mitigate the spread of STDs by eradicating the infection, preventing complications, and decreasing the risk of transmission to sexual partners. For instance, in October 2025, the US-based government agency, Minority HIV/AIDS Fund (MHAF), stated that an estimated 39.9 million individuals worldwide were living with HIV in 2023, comprising 38.6 million adults and 1.4 million children, when compared to prior years. Thus, the increasing occurrence of sexually transmitted diseases is driving the expansion of the chlamydia market.

Which Segment Categories Define The Chlamydia Market?

The chlamydia market covered in this report is segmented –

1) By Test Type: Culture Tests, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Tests, Other Test Types

2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration

3) By End User: Hospitals, Diagnostic Centers, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Culture Tests: Urethral Swab Culture, Endocervical Swab Culture, Urine Culture Test, Conjunctival Swab Culture

2) By Nucleic Acid Amplification Test (NAAT): PCR (Polymerase Chain Reaction), Transcription-Mediated Amplification (TMA), Strand Displacement Amplification (SDA), Loop-Mediated Isothermal Amplification (LAMP)

3) By Direct Fluorescent Antibody Test: DFA Test For Urogenital Chlamydia, DFA Test For Ocular Chlamydia, DFA For Respiratory Chlamydia Detection

4) By Serology Tests: Enzyme-Linked Immunosorbent Assay (ELISA), Immunofluorescence Assay (IFA), Western Blot

5) By Other Test Types: Immunochromatographic Rapid Test, Lateral Flow Immunoassay, Hybrid Capture Test (HCT)

What Trends Are Projected To Affect The Chlamydia Market?

Leading companies within the chlamydia market are concentrating on developing innovative solutions, such as the advancement of point-of-care molecular diagnostics, to enable quicker, more accurate onsite detection and improve timely treatment outcomes. The expansion of point-of-care molecular diagnostics refers to the broader adoption of rapid, onsite molecular tests that allow immediate detection of infections like chlamydia without requiring centralized laboratories. For instance, in January 2025, F. Hoffmann-La Roche AG, a Switzerland-based healthcare company, received FDA 510(k) clearance along with a CLIA waiver for its cobas liat molecular tests, which are specifically designed to diagnose sexually transmitted infections (STIs) directly at the point of care. These tests feature multiplex assay panels capable of detecting and differentiating multiple STIs, including chlamydia, gonorrhea, and Mycoplasma genitalium, from a single patient sample, with results becoming available in 20 minutes or less.

Who Are The Top Companies Competing In The Chlamydia Market?

Major companies operating in the chlamydia market are Siemens Healthineers, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, Hologic Inc, Quidel Corporation, Bio-Rad Laboratories Inc, Ortho Clinical Diagnostics, DiaSorin SpA, Eiken Chemical Co Ltd, MedMira Inc, GenMark Diagnostics Inc, ACON Laboratories Inc, Biocartis Group NV, Inova Diagnostics Inc, Trinity Biotech Plc, Seegene Inc, Qiagen NV, Binx Health Inc, Chembio Diagnostics Inc, Visby Medical Inc.

Read the full chlamydia market report here:

https://www.thebusinessresearchcompany.com/report/chlamydia-global-market-report

Which Regions Are Projected To Dominate The Chlamydia Market In The Coming Years?

North America was the largest region in the chlamydia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chlamydia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Chlamydia Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21138&type=smp

Browse Through More Reports Similar to the Global Chlamydia Market 2026, By The Business Research Company

Sciatica Global Market Report

https://www.thebusinessresearchcompany.com/report/sciatica-global-market-report

Physical Therapy Global Market Report

https://www.thebusinessresearchcompany.com/report/physical-therapy-global-market-report

Homeopathy Global Market Report

https://www.thebusinessresearchcompany.com/report/homeopathy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795